ARTHQ (Arch Therapeutics) Total Stockholders Equity: $-12.56 Mil (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARTHQ Arch Therapeutics Inc ARTHQ
12 GF Score
Price $0.00
View Full Analysis

What is Arch Therapeutics Total Stockholders Equity?

Arch Therapeutics ARTHQ -99.00% 12 Total Stockholders Equity is $-12.56 Mil as of Jun. 2024. GuruFocus rates ARTHQ with a GF Score™ of 12/100.

Arch Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2024 was $-12.56 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Arch Therapeutics's Book Value per Share for the quarter that ended in Jun. 2024 was $-2.83. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Arch Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2024 was -0.75.

Arch Therapeutics  (OTCPK:ARTHQ) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Arch Therapeutics's Book Value per Share for the quarter that ended in Jun. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-12.561-0)/4.444
=-2.83

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Arch Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(9.388 + 0) / -12.561
=-0.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arch Therapeutics Total Stockholders Equity Related Terms

Arch Therapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Arch Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arch Therapeutics Total Stockholders Equity Chart

Arch Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.81 -1.50 -1.03 -4.19 -7.51

Arch Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.02 -7.51 -9.58 -10.88 -12.56
ARTHQ
12GF Score
Arch Therapeutics Inc ARTHQ
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $-12.56 Mil mean?
Arch Therapeutics (ARTHQ) has a Total Stockholders Equity of $-12.56 Mil as of Jun. 2024. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Arch Therapeutics and its competitors.
Is Arch Therapeutics' Total Stockholders Equity too high?
Arch Therapeutics' current Total Stockholders Equity is $-12.56 Mil. Overall, Arch Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Arch Therapeutics' Total Stockholders Equity compare to GRTSQ and MTEM?
Arch Therapeutics' Total Stockholders Equity of $-12.56 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Arch Therapeutics and its competitors. Arch Therapeutics's current Total Stockholders Equity is $-12.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arch Therapeutics stock overvalued right now?
Arch Therapeutics (ARTHQ) has a current Total Stockholders Equity of $-12.56 Mil. The current Total Stockholders Equity is $-12.56 Mil. Arch Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Arch Therapeutics (ARTHQ), the current Total Stockholders Equity is $-12.56 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Arch Therapeutics Business Description

Address 235 Walnut Street, Suite 6, Framingham, MA, USA, 01702
Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.
12GF Score

Get the complete analysis for ARTHQ

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price